Close Menu

PGRN

The Pharmacogenomics Clinical Annotation Tool interprets variants from sequencing or genotyping tests and generates a report to inform prescribing decisions.

NEWYORK (GenomeWeb) – Personalized medicine proponents have long argued that pharmacogenomics can increase drug efficacy and reduce dangerous adverse outcomes, especially if PGx information is collected and stored preemptively so that it can be available at the point of prescribing and useful in

An international research team, led by investigators at the Mayo Clinic and National Institutes of Health's Pharmacogenomics Research Network, has identified a set of SNPs with promise as a tool to guide more personalized preventive breast cancer therapy using selective estrogen

Starting this fall, researchers will use an online system developed by Sage Bionetworks to at once collaboratively share data and compete to develop a genetic predictor that can identify rheumatoid arthritis patients who are likely to respond to immunosuppressive anti-TNF therapi

"Looking at drug-response genetics and looking at disease genetics are very parallel processes," said Ron Krauss, senior scientist and director of atherosclerosis research at Children's Hospital Oakland Research Institute in California.

With the additional funding, "we are going to develop literature-mining tools to extract information automatically to speed up our curation," Russ Altman, principal investigator in PharmGKB, said this week. The added NIH funds will also be used to annotate the whole-genome sequence data of a family, which Altman cannot yet identify.

With this new funding, the NIH hopes to continue PGx research in existing focus areas of cancer, heart disease, asthma, and nicotine addiction, and also to expand into new areas, including rheumatoid arthritis and bipolar disorder.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.